Th1902
Web2 days ago · Recent Highlights: Sudocetaxel Zendusortide (“TH1902”) Development Pathway . On December 1, 2024, Theratechnologies announced the decision to voluntarily pause … Web12 Apr 2024 · Q1 2024 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised...
Th1902
Did you know?
Web27 Jul 2024 · TH1902 also blocked cell cycle progression in the G2/M phase confirming that, once internalized, docetaxel is effectively released from the conjugate. 56-58 The rapid … Web12 Sep 2024 · First evidence for TH1902 targeting of human breast and ovarian cancer stem-like cells in vitro and in vivo; Paper highlights potential mechanisms by which TH1902 can bypass underlying causes of resistance to docetaxel that can contribute to treatment failure and disease recurrence
Web1 day ago · That’s the take from Leede Jones Gable analyst Douglas W. Loe, who in a Wednesday review of the latest quarterly results reiterated a “Speculative Buy” rating on the stock and C$3.75 target ... Web12 Jul 2024 · TH1902 enables the delivery of the chemotherapeutic agent directly into cancer cells through the recognition and internalizing function of a protein called sortilin, which is overexpressed on the surface of the cells. These major scientific advances have driven the launch of clinical studies in patients suffering from hard-to-treat solid tumors ...
WebNational Center for Biotechnology Information Web14 Jul 2024 · This is Theratechnologies’ first-in-human study of TH1902, its investigational lead peptide drug conjugate (“PDC”) linked to docetaxel for the treatment of sortilin-expressing cancers. It has...
WebTH1902 is the Company’s lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology. TH1902 is currently being evaluated in a Phase 1 clinical trial, …
Web8 Apr 2024 · TH1902 as a single agent inhibited ovarian tumor growth more than either of the unconjugated taxanes or carboplatin. Furthermore, TH1902 combination with … hubbell construction iaWeb13 Aug 2024 · TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. The FDA granted fast … hoggson \\u0026 pettis mfg coWebTheratechnologies Inc. recently announced new preclinical in vivo findings regarding the efficacy and tolerability of its novel investigational proprietary peptide-drug conjugate (PDC), TH1902, for the treatment of several cancer types expressing the sortilin receptor (SORT1+) as shown in the table below.. New preclinical in vivo results in colorectal, pancreatic, … hubbell contacts phone numberWeb2 days ago · Theratechnologies voluntarily halted patient enrollment in its TH1902 basket trial in December 2024. Following advice from the Scientific Advisory Committee (SAC) in March 2024, the company is expected to file a revised Sudocetaxel Zendusortide (TH1902) Phase 1 trial protocol with the US Food and Drug Administration (FDA) by the end of April … hoggs of fife wax jacketsWeb12 Aug 2024 · TH1902 was able to induce apoptotic cell death faster than free docetaxel. TH1902 also blocked cell cycle progression in the G2/M phase confirming that, once … hubbell constructionWebSudocetaxel Zendusortide ("TH1902") Development Pathway. On December 1, 2024, Theratechnologies announced the decision to voluntarily pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate ("PDC") for the treatment of sortilin-expressing cancers. hubbell contact numberWeb14 Mar 2024 · TH1902 is currently being evaluated in a Phase 1 clinical trial, although patient recruitment was voluntarily paused on December 1, 2024. In alignment with this decision, the FDA placed the trial ... hubbell connectors